Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term inhibitor. Found 26 abstracts

no pagination
Nilov D, Maluchenko N, Kurgina T, Pushkarev S, Lys A, Kutuzov M, Gerasimova N, Feofanov A, Svedas V, Lavrik O, Studitsky VM. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. International journal of molecular sciences. 2020 Mar 20;21(6).   PMCID: PMC7139824
Lentz CS, Halls VS, Hannam JS, Strassel S, Lawrence SH, Jaffe EK, Famulok M, Hoerauf A, Pfarr KM. wALADin Benzimidazoles Differentially Modulate the Function of Porphobilinogen Synthase Orthologs. Journal of medicinal chemistry. 2014 Mar;57(6):2498-510.   PMCID: PMC 3983392
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Menges CW, Sementino E, Talarchek J, Xu JF, Chernoff J, Peterson JR, Testa JR. Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf-MAPK Pathways. Molecular Cancer Research. 2012 Sep;10(9):1178-88.   PMCID: PMC3447107
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan JY, Valota O, Martell B, Hariharan S, Figlin RA. Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 2012 Apr;30(12):1371-7.   PMCID: not NIH funded
Van der Veken P, Fulop V, Rea D, Gerard M, Van Elzen R, Joossens J, Cheng JD, Baekelandt V, De Meester I, Lambeir AM, Augustyns K. P2-Substituted N-Acylprolylpyrrolidine Inhibitors of Prolyl Oligopeptidase: Biochemical Evaluation, Binding Mode Determination, and Assessment in a Cellular Model of Synucleinopathy. Journal of medicinal chemistry. 2012 Nov;55(22):9856-67.   PMCID: No NIH
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the Antiapoptotic Protein Survivin in Colon Cancer. Clinical Colorectal Cancer. 2011 Sep;10(3):188-93.   PMCID: not NIH funded
Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Annals of Oncology. 2011 Nov;22(11):2523-9.   PMCID: not NIH funded
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 2011 Nov;17(22):7194-203.   PMCID: PMC3570203
Betancourt AM, Eltoum IA, Desmond RA, Russo J, Lamartiniere CA. In Utero Exposure to Bisphenol A Shifts the Window of Susceptibility for Mammary Carcinogenesis in the Rat. Environmental Health Perspectives. 2010 Nov;118(11):1614-9.   PMCID: PMCID: PMC2974702
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Zhao RB, Gish K, Murphy M, Yin YX, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes & development. 2000 Apr 15;14(8):981-93.
Moraleda G, Seeholzer S, Bichko V, Dunbrack R, Otto J, Taylor J. Unique properties of the large antigen of hepatitis delta virus. Journal of Virology. 1999 Sep;73(9):7147-52.
Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology. 1998 Oct;16(10):3345-52.
Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British Journal of Cancer. 1998 Nov;78(10):1329-36.
Oreilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A gynecologic oncology group study. Journal of Clinical Oncology. 1997 Jan;15(1):177-86.
Xiang BS, Markham GD. The conformation of inosine 5'-monophosphate (IMP) bound to IMP dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy. Journal of Biological Chemistry. 1996 Nov;271(44):27531-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term inhibitor

inhibitor trial cancer sunitinib breast-cancer solid tumors growth dose imatinib phosphorylation receptor bevacizumab survival carcinomas pharmacokinetics endothelial growth-factor cisplatin tyrosine kinase long metastatic colorectal-cancer interferon-alpha antitumor-activity imatinib mesylate infusion activation 7-methylguanine wild-type p53 efficacy poly(ADP-ribose) polymerase 1 in-vivo mycophenolic-acid topoisomerase I renal cell carcinoma isoprenylation guidelines enhancement mutations 2008 orge s-j clin oncol-v26 targeting survivin registry residual disease gene-expression progression nf2 placebo platinum-resistant pancreatic-cancer secondary structure prediction phase-ii raf kinase Network tiazofurin protein-levels volunteers disposition factor receptor validation molecular dynamics 1993 guchi t-cancer research-v53-p4349 Survivin acute-leukemia gene Apoptosis dna-damage fetal genome replication colorectal-cancer trapping kinase peptide aggregation oligomerization ulcerative-colitis taxol European Society of Medical Oncology phase I trial p53-regulated genes messenger-rna basal-like subtype topotecan 5-aminolevulinic acid dehydratase merlin gland prenylation KIT 2003 silva cm-pathol oncol res-v9-p13 drug platinum metastatic sequence polymerase chain-reaction spFRET microscopy heme-biosynthesis coatings gastrointestinal stromal tumors 2007 orge s-j clin oncol-v25 Colon cancer estrogen su11248 pseudomonas-aeruginosa National Comprehensive Cancer oligonucleotide microarrays AKT phase-ii trial kinase complexes transcriptional activation 1000 bchy a-clin canc res-v16-p5351 transformation cancer-cells invitro Immunohistochemistry b virus purification nucleosome EB-1 cells mammalian target cell lung-cancer therapeutic target targets erlotinib chemotherapy ovarian induced apoptosis 2008 matteo d-p am soc clin oncol-v26 GI147211 therapy pharmacodynamics growth-factor receptor gefitinib 100880 gastrointestinal tumors melanocyte-stimulating hormone refractory GG211 mesothelioma prognostic-factors nilotinib paclitaxel Ovarian clinical trial binding protein resistant prostate-cancer docking PI3K pathway regulated kinase expression camptothecin analogues protein-protein interactions morpheeins mechanism carcinoma
Last updated on Friday, August 07, 2020